Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia.

Chretien AS, Granjeaud S, Gondois-Rey F, Harbi S, Orlanducci F, Blaise D, Vey N, Arnoulet C, Fauriat C, Olive D.

Front Immunol. 2015 Nov 6;6:564. doi: 10.3389/fimmu.2015.00564. eCollection 2015.

2.

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.

Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci MJ, Delabesse E, Birnbaum D.

Oncotarget. 2015 Apr 10;6(10):8388-96.

3.

Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.

Collette Y, Prébet T, Goubard A, Adélaïde J, Castellano R, Carbuccia N, Garnier S, Guille A, Arnoulet C, Charbonier A, Mozziconacci MJ, Birnbaum D, Chaffanet M, Vey N.

Blood Cancer J. 2015 Mar 13;5:e292. doi: 10.1038/bcj.2015.13. No abstract available.

4.

Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia.

Saillard C, Etienne A, Charbonnier A, D'incan E, Rey J, Arnoulet C, Mozziconacci MJ, Blaise D, Vey N, Prebet T.

Leuk Lymphoma. 2014 Sep;55(9):2211-2. doi: 10.3109/10428194.2013.876497. Epub 2014 Jan 28. No abstract available.

PMID:
24354683
5.

Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.

Brecqueville M, Rey J, Devillier R, Guille A, Gillet R, Adélaide J, Gelsi-Boyer V, Arnoulet C, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D, Murati A.

Haematologica. 2014 Jan;99(1):37-45. doi: 10.3324/haematol.2013.091454. Epub 2013 Aug 30.

6.

Concomitant germ-line RUNX1 and acquired ASXL1 mutations in a T-cell acute lymphoblastic leukemia.

Prebet T, Carbuccia N, Raslova H, Favier R, Rey J, Arnoulet C, Vey N, Vainchenker W, Birnbaum D, Mozziconacci MJ.

Eur J Haematol. 2013 Sep;91(3):277-9. doi: 10.1111/ejh.12147. Epub 2013 Jun 28. No abstract available.

PMID:
23692290
7.

Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Gelsi-Boyer V, Cervera N, Bertucci F, Brecqueville M, Finetti P, Murati A, Arnoulet C, Mozziconacci MJ, Mills KI, Cross NC, Vey N, Birnbaum D.

Haematologica. 2013 Apr;98(4):576-83. doi: 10.3324/haematol.2012.071506. Epub 2012 Oct 12.

8.

Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction.

Prébet T, Jean E, Autret A, Charbonnier A, Rey J, Etienne A, D'incan E, Fürst S, Arnoulet C, Blaise D, Vey N.

Leuk Lymphoma. 2012 Nov;53(11):2186-91. doi: 10.3109/10428194.2012.685733. Epub 2012 Aug 7.

PMID:
22582970
9.

Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, Cervera N, Gelsi-Boyer V, Arnoulet C, Gisserot O, Verrot D, Slama B, Vey N, Mozziconacci MJ, Birnbaum D, Murati A.

Genes Chromosomes Cancer. 2012 Aug;51(8):743-55. doi: 10.1002/gcc.21960. Epub 2012 Apr 9.

PMID:
22489043
10.

Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS study.

Durrieu F, Geneviève F, Arnoulet C, Brumpt C, Capiod JC, Degenne M, Feuillard J, Garand R, Kara-Terki A, Kulhein E, Maynadié M, Ochoa-Noguera ME, Plesa A, Roussel M, Eghbali H, Truchan-Graczyk M, de Carvalho Bittencourt M, Feugier P, Béné MC.

Cytometry B Clin Cytom. 2011 Nov;80(6):346-53. doi: 10.1002/cyto.b.20613. Epub 2011 Oct 4.

11.

HLA-DR and B7-2 (CD86) monocyte expressions after major cancer surgery: profile in sepsis.

Mokart D, Textoris J, Chow-Chine L, Brun JP, Sannini A, Turrini O, Blache JL, Arnoulet C, Sainty D, Leone M.

Minerva Anestesiol. 2011 May;77(5):522-7.

12.

Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study.

Prebet T, Etienne A, Devillier R, Romeo E, Charbonnier A, D'incan E, Esterni B, Arnoulet C, Blaise D, Vey N.

Cancer. 2011 Mar 1;117(5):974-81. doi: 10.1002/cncr.25554. Epub 2010 Oct 18.

13.

Mutual benefits of B-ALL and HLDA/HCDM HLDA 9th Barcelona 2010.

Faure GC, Amsellem S, Arnoulet C, Bardet V, Campos L, De Carvalho-Bittencourt M, de Labarthe A, Eischen A, Feuillard J, Fossat C, Ottou FG, Guérin E, Guy J, Jouault H, Kuhlein E, Lacombe F, Lainey E, Maynadié M, Noguera ME, Roussel M, Solly F, Ballon OW, Béné MC; GEIL workshop..

Immunol Lett. 2011 Jan 30;134(2):145-9. doi: 10.1016/j.imlet.2010.10.008. Epub 2010 Oct 15.

PMID:
20951742
14.

ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.

Gelsi-Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, Finetti P, Murati A, Arnoulet C, Zerazhi H, Fezoui H, Tadrist Z, Nezri M, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D.

Br J Haematol. 2010 Nov;151(4):365-75. doi: 10.1111/j.1365-2141.2010.08381.x. Epub 2010 Sep 29.

PMID:
20880116
15.

The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome.

Prebet T, Lhoumeau AC, Arnoulet C, Aulas A, Marchetto S, Audebert S, Puppo F, Chabannon C, Sainty D, Santoni MJ, Sebbagh M, Summerour V, Huon Y, Shin WS, Lee ST, Esterni B, Vey N, Borg JP.

Blood. 2010 Sep 30;116(13):2315-23. doi: 10.1182/blood-2010-01-262352. Epub 2010 Jun 17.

16.

Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: a reference document based on a systematic approach by the GTLLF and GEIL.

Arnoulet C, Béné MC, Durrieu F, Feuillard J, Fossat C, Husson B, Jouault H, Maynadié M, Lacombe F.

Cytometry B Clin Cytom. 2010 Jan;78(1):4-10. doi: 10.1002/cyto.b.20484.

17.

A myeloproliferative disorder may hide another one.

Laibe S, Tadrist Z, Arnoulet C, Sainty D, Mozziconacci MJ.

Leuk Res. 2009 Aug;33(8):1133-6. doi: 10.1016/j.leukres.2009.01.034. Epub 2009 Feb 27.

PMID:
19250672
18.

Presence of a minor Philadelphia-positive clone in young adults with de novo T-cell ALL.

Prebet T, Mozziconacci MJ, Sainty D, Arnoulet C, Lafage M, Dastugue N, Charbonnier A, Coso D, Gastaut JA, Blaise D, Vey N.

Leuk Lymphoma. 2009 Mar;50(3):485-7. doi: 10.1080/10428190802601148. No abstract available.

PMID:
19197723
19.

Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study.

Lacombe F, Arnoulet C, Maynadié M, Lippert E, Luquet I, Pigneux A, Vey N, Casasnovas O, Witz F, Béné MC.

Leukemia. 2009 Feb;23(2):350-7. doi: 10.1038/leu.2008.296. Epub 2008 Nov 6.

PMID:
18987664
20.

Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.

Gelsi-Boyer V, Trouplin V, Adélaïde J, Aceto N, Remy V, Pinson S, Houdayer C, Arnoulet C, Sainty D, Bentires-Alj M, Olschwang S, Vey N, Mozziconacci MJ, Birnbaum D, Chaffanet M.

BMC Cancer. 2008 Oct 16;8:299. doi: 10.1186/1471-2407-8-299.

Supplemental Content

Loading ...
Support Center